Search results
Results from the WOW.Com Content Network
In the sole paper describing in vivo use of enzyme-activated MR contrast agents, the agent was delivered to embryonic cells via a micropipette. However, the authors of the paper acknowledge that this is not a feasible approach for many research projects, [5] and it presents a clear impediment to clinical use. There is active research in using ...
Allergic reactions are rare. [1] The use of barium during pregnancy is safe for the baby; however, X-rays may result in harm. [4] Barium sulfate suspension is typically made by mixing barium sulfate powder with water. [1] It is a non-iodinated contrast media. [5] Barium sulfate has been known since the Middle Ages. [6]
Gadopentetic acid, sold under the brand name Magnevist, is a gadolinium-based MRI contrast agent. [2]It is usually administered as a salt of a complex of gadolinium with DTPA (diethylenetriaminepentacetate) with the chemical formula A 2 [Gd(DTPA)(H 2 O)]; when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine".
DOTA is derived from the macrocycle known as cyclen.The four secondary amine groups are modified by replacement of the N-H centers with N-CH 2 CO 2 H groups. The resulting aminopolycarboxylic acid, upon ionization of the carboxylic acid groups, is a high affinity chelating agent for di- and trivalent cations.
The contrast medium that is used usually produces a sensation of warmth lasting only a few seconds, but may be felt in a greater degree in the area of injection. If the patient is allergic to the contrast medium, much more serious side effects are inevitable; however, with new contrast agents the risk of a severe reaction is less than one in ...
Treatment effect An effect attributed to a treatment in a clinical trial. In most clinical trials the treatment effect of interest is a comparison (or contrast) of two or more treatments. (ICH E9) Treatment emergent An event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state. (ICH E9)
Gadobutrol contrast media is a clear, colorless-to-pale yellow solution of 1 mmol/mL formulation, available in single dose vials (2 mL, 7.5 mL, 10mL, and 15 mL), single dose pre-filled injections (7.5 mL, 10 mL, 15 mL), and pharmacy bulk packages (30 mL and 65 mL) containing multiple vials. [19]
A low osmolar contrast agent with concentration of 200 to 300 mg per ml with volume of 20 ml can be used in this study. Warming the contrast medium before infusion into the urethra can help to reduce the chance of getting spasm of external urethral sphincter. [4] The subject lies down in a supine position.